BioRationality: New FDA Guideline Invites Biosimilar Developers to Reduce the Cost of Testing
June 12th 2023Sarfaraz K. Niazi, PhD, examined the new FDA guideline that acts as an invitation to biosimilar developers to decrease the cost of testing, potentially opening the door for companies to reduce nonclinical testing of biosimilars entirely.
Dr Fran Gregory: Providing Patients With High-Quality Biosimilars Is a Collaborative Effort
June 11th 2023Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the importance of collaboration between all stakeholders to boost confidence in providing patients with a biosimilar drug.
Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar
June 1st 2023The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.
Samsung Bioepis' Eculizumab Biosimilar Approved in Europe
May 31st 2023The European Commission has granted marketing authorization to Samsung Bioepis' biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, is the first hematology biosimilar from Samsung Bioepis to be approved in the European Union.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Biosimilar Acceptance Takes Time but Policy Intervention Is Needed, Panelists Say
May 25th 2023A group of panelists at Asembia 2023 shared the bigger role that pharmacists, payers, and providers can play in growing biosimilar acceptance and championing policy changes that boost biosimilar utilization.